ClinicalTrials.gg
RecruitingNCT07863232Updated Oct 7, 2026

Melatonin and Immunonutrition for Pain Relief in Fibromyalgia

An interventional study of Melatonin 1mg and intravenous B-complex vitamin drip and Placebo in Fibromyalgia, sponsored by University of Thessaly. Recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Thessaly · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Fibromyalgia (FMS) is characterized by chronic musculoskeletal pain, sleep disturbances, and fatigue. It is not entirely clear how Bcomplex vitamins affect the human pain system, while at the same time there have been approaches that use melatonin in patients with FMS and report improvements in pain and sleep quality.

The purpose of this study is to investigate the efficacy of a combined immunonutrition and melatonin intervention in patients with FMS through a randomized clinical trial (RCT). The combined effect of immunonutrition and melatonin, administered intravenously once a week and orally respectively, versus placebo, will be examined in patients with FMS, for a period of 5 weeks. The primary endpoints concern the quantification of pain and quality of life, while the secondary endpoints are sleep quality, fatigue and inflammatory markers.

Read the detailed description

Recent data have shown the potential role of melatonin as an adjuvant treatment in fibromyalgia (FMS), as it appears to improve sleep quality, reduce pain, and improve patient- and physician-reported assessments of quality of life. In addition to melatonin, intravenous micronutrient therapy has also been reported to improve symptoms in patients with fibromyalgia. More specifically, the intravenous administration of a mixture of vitamins and trace elements has been associated with reductions in pain, fatigue, and the number of tender points, as well as improvements in mood, quality of life, and energy levels for daily activities in patients with FM. Following a review of the available literature, a randomized, placebo-controlled clinical trial will be conducted to evaluate the efficacy of the combined administration of melatonin and intravenous vitamin drip in patients with FMS compared with a control group receiving placebo.

The primary outcomes will include changes in pain and quality of life, assessed using the following validated instruments: the Visual Analogue Scale (VAS), the Revised Fibromyalgia Impact Questionnaire (FIQR), the Functional Assessment of Chronic Illness Therapy (FACIT), and the Brief Pain Inventory (BPI). Additional primary outcome measures will include the patient's subjective perception of change, assessed using the Patient Global Impression of Change (PGIC), and the degree of central sensitization, assessed using the Central Sensitization Inventory (CSI).

The secondary outcomes will include changes in sleep-related symptoms, assessed using the Epworth Sleepiness Scale (ESS); changes in fatigue, assessed using the Fatigue Severity Scale (FSS); changes in psychological symptoms, assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI); and changes in inflammatory markers, specifically C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

02

Conditions studied

  • Fibromyalgia

Keywords

  • immunonutrition
  • FMS
  • melatonin
  • vitamins
  • pain
  • sleep
  • quality of life
03

In context

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 938 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

University of Thessaly is the lead sponsor of 195 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients diagnosed with Fibromyalgia Speak and understand the Greek language Consent to participate

Exclusion criteria

Exclusion Criteria:

Children and adolescents Diagnosed with other chronic pain disorders or disease Recent modification of their treatment (within 3 months) Pregnant and breastfeeding women Patients with severe renal or cardiac disease, cancer, infection, epilepsy

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Immunonutrition

    Per os Melatonin 1mg every night half an hour before sleep and intravenous B-complex vitamin drip every week

    Dietary Supplement: Melatonin 1mg and intravenous B-complex vitamin drip

  • Placebo comparator
    Placebo

    Per os corn startch placebo capsules every night half an hour before sleep and intravenous N/S 500mL drip every week

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementMelatonin 1mg and intravenous B-complex vitamin drip

    Drug page: MelatoninStudies of MelatoninMelatonin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive Melatonin 1mg half an hour before sleep every day and intravenous B-complex vitamin drip every week for a total of five weeks

  • Dietary supplementPlacebo

    Per os corn startch placebo capsules every night half an hour before sleep and intravenous N/S 500mL drip every week

06

What researchers measure

Primary outcomes

  1. VAS pain

    Pain on a scale from 0 to 10 where 0 indicates "no pain" and 10 indicates "the worst possible pain"

    Time frame: 5 weeks

  2. Brief Pain Inventory (BPI)

    Time frame: 5 weeks

  3. Revised Fibromyalgia Impact Questionnaire (FIQR)

    Time frame: 5 weeks

  4. Functional Assessment of Chronic Illness Therapy (FACIT)

    Time frame: 5 weeks

  5. Patient Global Impression of Change (PGIC)

    Time frame: 5 weeks

  6. Central Sensitization Inventory (CSI)

    Time frame: 5 weeks

Secondary outcomes

  1. Epworth Sleepiness Scale (ESS)

    Time frame: 5 weeks

  2. Fatigue Severity Scale (FSS)

    Time frame: 5 weeks

  3. Inflammatory markers

    CRP, ESR

    Time frame: 5 weeks

  4. Beck Depression Inventory (BDI)

    Time frame: 5 weeks

  5. Beck anxiety inventory (BAI)

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
  • Immunonutrition Unit, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
    Larissa, 41100, Greece
    Recruiting
    • Arriana Gkouvi, MD, PhDc · Contactargkouvi@uth.gr · 00302413502875
    • Maria G. Grammatikopoulou, As Professor · Contactmgrammat@uth.gr · 00302413502813
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863232
Responsible party
Arriana Gkouvi (MD, MSc, PhDc, University of Thessaly) — Principal investigator
First posted
Oct 7, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Arriana Gkouvi, MD, MSc, PhDc
Contact
argkouvi@uth.gr
00302413502875
Maria G. Grammatikopoulou, Assistant Professor
Contact
mgrammat@uth.gr
2413502813
Maria G. Grammatikopoulou, Assistant Professor
principal investigator · Assistant Professor on Nutrition-Dietetics, at the Department of Medicine, University of Thessaly, Greece

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion